Linagliptin Added to Sulphonylurea in Uncontrolled Type 2 Diabetes Patients With Moderate-To-Severe Renal Impairment

Diabetes and Vascular Disease Research - United Kingdom
doi 10.1177/1479164113507068
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment

Clinical Pharmacology in Drug Development
PharmacologyPharmaceutical Science
2018English

1004-P: Oral Semaglutide vs. Placebo in Patients With Type 2 Diabetes and Moderate Renal Impairment: PIONEER 5

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Pleiotropic Effects of Liraglutide in Patients With Type 2 Diabetes and Moderate Renal Impairment: Individual Effects of Treatment

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

54-Or: Oral Semaglutide vs. Empagliflozin Added on to Metformin Monotherapy in Uncontrolled Type 2 Diabetes: PIONEER 2

Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Prevalence of Undiagnosed Glucose Intolerance and Type 2 Diabetes in Patients With Moderate-To-Severe Obstructive Sleep Apnea Syndrome

Sleep and Breathing
OtorhinolaryngologyNeurology
2019English

Prescription of DPP-4 Inhibitors to Type 2 Diabetes Mellitus Patients With Renal Impairment: A UK Primary Care Experience

Clinical Therapeutics
Pharmacology
2018English

A Review of Sitagliptin With Special Emphasis on Its Use in Moderate to Severe Renal Impairment

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2013English

Living With Moderate to Severe Renal Failure From the Perspective of Patients

BMC Nephrology
Nephrology
2016English

Limitations and Future Treatment Options in Type 2 Diabetes With Renal Impairment

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy